GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » EV-to-Revenue

Pharmesis International (SGX:BFK) EV-to-Revenue : 0.41 (As of May. 29, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pharmesis International's enterprise value is S$3.53 Mil. Pharmesis International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was S$8.55 Mil. Therefore, Pharmesis International's EV-to-Revenue for today is 0.41.

The historical rank and industry rank for Pharmesis International's EV-to-Revenue or its related term are showing as below:

SGX:BFK' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.31   Med: 0.21   Max: 1.3
Current: 0.42

During the past 13 years, the highest EV-to-Revenue of Pharmesis International was 1.30. The lowest was -0.31. And the median was 0.21.

SGX:BFK's EV-to-Revenue is ranked better than
93.44% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.315 vs SGX:BFK: 0.42

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), Pharmesis International's stock price is S$0.08. Pharmesis International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.33. Therefore, Pharmesis International's PS Ratio for today is 0.24.


Pharmesis International EV-to-Revenue Historical Data

The historical data trend for Pharmesis International's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International EV-to-Revenue Chart

Pharmesis International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.74 0.42 0.25 0.54

Pharmesis International Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 - 0.25 - 0.54

Competitive Comparison of Pharmesis International's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmesis International's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmesis International's EV-to-Revenue falls into.



Pharmesis International EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pharmesis International's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.526/8.553
=0.41

Pharmesis International's current Enterprise Value is S$3.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was S$8.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmesis International  (SGX:BFK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pharmesis International's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.08/0.327
=0.24

Pharmesis International's share price for today is S$0.08.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was S$0.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmesis International EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmesis International's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmesis International (SGX:BFK) Business Description

Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its geographical segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International (SGX:BFK) Headlines